PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

New York University (NYU) Clinical Cancer Center, New York

Fox Chase Cancer Center, Philadelphia

Virginia Cancer Specialists, Fairfax

Hospital Universitario La Paz, Servicio de Oncología, Madrid

Centro Integral Oncologico Clara Campal, START Madrid, Madrid

Hospital Universitario Quiron de Madrid, Madrid

Florida Cancer Specialists, Lake Mary

The Sarah Cannon Research Institute, Nashville

Forrest General Cancer Center, Hattiesburg

Barbara Ann Karmanos Cancer Institute, Detroit

START Midwest, Grand Rapids

Washington University - St. Louis, St Louis

MD Anderson Cancer Center, Houston

University of Southern California, Los Angeles

California Cancer Associates for Research and Excellence, Encinitas

Providence Portland Medical Center, Portland

University of Alabama at Birmingham, Birmingham

Yale Cancer Center, New Haven

Seoul National University Hospital, Seoul

Kangbuk Samsung Hospital, Seoul

Severance Hospital- Yonsei Cancer Center, Seoul

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Clinic de Barcelona, Barcelona

The Christie NHS Foundation Trust, Withington

Beatson, West of Scotland Cancer Centre, Glasgow